These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 32203500)
1. Advanced case of PKDL due to delayed treatment: A rare case report. Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500 [TBL] [Abstract][Full Text] [Related]
2. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277 [TBL] [Abstract][Full Text] [Related]
3. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478 [TBL] [Abstract][Full Text] [Related]
5. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states. Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161 [TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis. Pijpers J; den Boer ML; Essink DR; Ritmeijer K PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620 [TBL] [Abstract][Full Text] [Related]
8. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
9. An unusual paediatric case of post-kala-azar dermal leishmaniasis: a hidden parasite under the veil of white. Arora A; Mohta A Clin Microbiol Infect; 2023 Jun; 29(6):803-804. PubMed ID: 36918142 [No Abstract] [Full Text] [Related]
10. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis. Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451 [TBL] [Abstract][Full Text] [Related]
11. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis. Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208 [TBL] [Abstract][Full Text] [Related]
12. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. Pandey K; Das VN; Singh D; Das S; Lal CS; Verma N; Bimal S; Topno RK; Siddiqui NA; Verma RB; Sinha PK; Das P J Clin Microbiol; 2012 Apr; 50(4):1478-9. PubMed ID: 22278840 [TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. Sundar S; Singh A; Chakravarty J; Rai M ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839 [TBL] [Abstract][Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine. Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349 [TBL] [Abstract][Full Text] [Related]
16. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204 [TBL] [Abstract][Full Text] [Related]
17. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone. Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363 [TBL] [Abstract][Full Text] [Related]
18. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. Abongomera C; Battaglioli T; Adera C; Ritmeijer K Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722 [TBL] [Abstract][Full Text] [Related]
19. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL). Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040 [TBL] [Abstract][Full Text] [Related]
20. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis. Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]